Stock Analysis
argenx SE American Depositary SharesARGX
P/E 39.66×· 5Y range 33.93–72.74×· bottom 8% of history
Sector: Healthcare
AnalystsStrong Buy25 analystsP/E 39.7× sits at the 8th percentile of its 5.089664613278576-year history.
Cash covers 11030% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Profitability90
- Financial Health75
Risks
- Quality42
- Growth50
Mixed business trading cheap — priced for skepticism.
Market context
-3.2% today· Z 0.8σ
Bull Case
- ✓Altman Z 21.7 — safe-zone balance sheet
- ✓ROE 15.4% — efficient capital deployment
- ✓Revenue CAGR 68.3% — durable top-line growth
- ✓P/E 39.7× at bottom 8% of 5-year history
What's happening with ARGX
Profile
Strong profitability and financial health; moat, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation35/100 · Weak
- P/E vs own history (8th pct)25/25
- FCF yield (1.9%)5/25
- P/S (12.2x)5/25
- EV/EBIT (44.0x)0/25
- Growth50/100 · Moderate
- Revenue CAGR (68.3%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (46.9%)25/25
- Profitability90/100 · Strong
- ROIC (25.4%)25/25
- ROE (15.4%)20/25
- Net margin (30.5%)25/25
- Operating margin (24.9%)20/25
- Financial Health75/100 · Strong
- Altman Z (21.72)25/25
- Current ratio (5.12)25/25
- Interest coverage (-81.9x)0/25
- Net cash / debt (Net cash)25/25
- Quality42/100 · Weak
- Piotroski F (6/9)15/25
- Beneish M (-1.91)12/25
- FCF conversion (75%)15/25
- Margin stability (σ 65.8%)0/25
- Moat11/100 · Weak
- ROIC >12% years (1/5 yrs)0/25
- Median gross margin (23.0%)6/25
- FCF-positive years (2/5 yrs)5/25
- Worst-year net margin (worst -160.9%)0/25
Risk Flags
- ⚠SBC 6.0% of revenue — real dilution cost
- ⚠3 loss-making years in recent history
- ⚠Interest coverage -81.9× — thin debt cushion
About argenx SE American Depositary Shares
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. Show more
The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,863 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
35DP/E (TTM)39.7xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 33.9x–72.7x · 8th pct
P/FCF64.2xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.9%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -6.1%–2.2% · 96th pct
P/S (TTM)12.16xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 10.3x–73.6x · 3rd pct
EV/EBIT44.0xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 36.7x–61.4x · 17th pct
EV/Sales8.7xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E27.0xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.12xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.95A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
90A+ROIC25.4%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE15.4%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA18.9%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin30.5%A
Grade A: HighNet Income / Revenue
Operating Margin24.9%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin57.2%A
Grade A: PremiumGross Profit / Revenue
FCF Margin22.9%A
Grade A: HighFCF / Revenue
True FCF Margin16.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
50CRevenue CAGR68.3%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth46.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income19.7%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue6.0%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score21.72A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.12xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.52xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-81.9xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.01xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt110.30xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
42D+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-1.91C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion75.1%C
Grade C: AverageFCF / Net Income
Margin Stability65.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.61xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
11EROIC >12% Years1/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)23.0%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years2/5 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-160.9%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$20.65
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$82.89
Cash & short-term investments per share (Finnhub)
Book Value / Share$134.59
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$47.00M
Total debt obligations (short + long term)
Cash & Equiv.$5.18B
Cash and short-term investments
Net Debt$-5.14BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$8.42B
Shareholders' equity (book value)
Asset / Liability6.21xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$51.51B
Current Market Capitalization
Beta1.54C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Dec 2025 · Ratio snapshot Oct 17, 2026
Key Insights: argenx SE American Depositary Shares (ARGX)
ARGX is down 3.21% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for argenx SE American Depositary Shares. Altman Z-Score of 21.72 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Revenue has compounded at roughly 68% annually — a strong growth profile.
- argenx SE American Depositary Shares converts about 23% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Interest coverage of -81.9× leaves little room for earnings shocks.
- argenx SE American Depositary Shares posted a net loss in 3 of 5 available completed fiscal years (2021–2025).
See how ARGX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ARGX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 8 | Pre-market | 819.98 | -11.68% | -9.51 |
| Oct 8 | Regular | 823.78 | -11.27% | -9.15 |
| Oct 8 | After-hours | 819.80 | -11.70% | -9.53 |
| Oct 6 | After-hours | 931.35 | +2.02% | 2.09 |
Frequently Asked Questions about ARGX
What is the current argenx SE American Depositary Shares (ARGX) stock price?
ARGX is trading at $819.14 at the last market close, down 3.21% on the session. PreMarketPrice tracks ARGX pre-market, intraday and after-hours prices.
Is ARGX stock a buy right now?
PreMarketPrice's quantitative model rates argenx SE American Depositary Shares's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ARGX stock overvalued?
argenx SE American Depositary Shares trades at a trailing P/E of 39.7 and our valuation score rates it 35/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does argenx SE American Depositary Shares report earnings?
No confirmed earnings date is currently scheduled for ARGX. The Earnings section lists recent reports and updates as dates are announced.
What sector does argenx SE American Depositary Shares operate in?
argenx SE American Depositary Shares operates in the Healthcare sector. The Related Stocks section lists sector peers for comparison.
What does argenx SE American Depositary Shares do?
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases.
About argenx SE American Depositary Shares (ARGX) Stock
argenx SE American Depositary Shares (ARGX) is a US-listed stock operating in the Healthcare sector. As of the latest update, argenx SE American Depositary Shares is trading at $819.14, down 3.21% on the day with a market capitalization of $51.5 billion. The financial health score for ARGX is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ARGX stock.
ARGX Stock Analysis & Key Metrics
On PreMarketPrice, you can track argenx SE American Depositary Shares (ARGX) across multiple dimensions:
- Pre-market price & movement: Real-time ARGX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ARGX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for argenx SE American Depositary Shares across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ARGX.
- Sector peers: Compare ARGX against 4 other healthcare stocks on key financial metrics.
Is ARGX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate argenx SE American Depositary Shares (ARGX) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.argenx SE American Depositary Shares (ARGX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.